United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

leo pharma - betamethasone dipropionate; calcipotriol monohydrate - cutaneous gel - 500microgram/1gram ; 50microgram/1gram

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin 15 [usp'u] - bleomycin for injection, usp should be considered a palliative treatment. it has been shown to be useful in the management of the head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin is poorer in patients with previously irradiated head and neck cancer. hodgkin's disease, non-hodgkin's lymphoma. embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin for injection, usp has also been shown to be useful in the management of: bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin is contraindicated in patients who have demonstrated a hypersensitive or an idiosyncratic reaction to it.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - fusidic acid -

Malta - English - Medicines Authority

leo pharma a/s - fusidic acid - cream - fusidic acid - antibiotics and chemotherapeutics for dermatological use

European Union - English - EMA (European Medicines Agency)

leo pharma a/s - brodalumab - psoriasis - immunosuppressants - kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin 15000 [iu] - palliation and treatment adjutant to surgery and radiation therapy of the following neoplasms: - squamous cell carcinoma of the skin, head and neck, and esophagus (primary indication). - squamous cell carcinoma of the larynx, penis and uterine cervix. - squamous cell carcinoma of the bronchus (response infrequent). - ch0riocarcinoma and embryonal cell carcinoma of the testis. - advanced hodgkin’s disease and other lymphomas. - mycosis fungoides. note . use of bleomycin after radiation therapy is less successful than use before radiation therapy. bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - hydrocortisone butyrate - cutaneous ointment - 1mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - zinc acetate; erythromycin - cutaneous solution - 12mg/1ml ; 40mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - hydrocortisone butyrate - cutaneous cream - 1mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - hydrocortisone butyrate - cutaneous cream - 1mg/1gram